Christopher Hoimes, DO

Instructor in the Department of Medicine
Email address christopher.hoimes@duke.edu

Education and Training

  • Fellowship, Medical Oncology, Yale University, 2006 - 2009
  • Residency, Internal Medicine, Penn State Milton S. Hershey Medical Center, 2002 - 2005
  • D.O., New York Institute of Technology, College of Osteopathic Medicine, 2001

Publications

Esagian, Stepan M., Ali Raza Khaki, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Joseph J. Park, et al. “Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.” Bju Int, February 8, 2021. https://doi.org/10.1111/bju.15324.

PMID
33556233
Full Text

Wang, Xinning, Aditi Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, et al. “Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.” Cancers (Basel) 13, no. 3 (January 22, 2021). https://doi.org/10.3390/cancers13030417.

PMID
33499427
Full Text

Nelson, A. A., R. J. Cronk, E. A. Lemke, A. Szabo, A. R. Khaki, L. N. Diamantopoulos, P. Grivas, et al. “Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.” Bladder Cancer 7, no. 1 (January 1, 2021): 33–42. https://doi.org/10.3233/BLC-200377.

Full Text

Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.

PMID
33115529
Full Text

Shieh, Alice C., Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya, and Sree Harsha Tirumani. “Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.” Abdom Radiol (Ny) 45, no. 10 (October 2020): 3028–35. https://doi.org/10.1007/s00261-019-02334-3.

PMID
31754740
Full Text

Ansari-Gilani, Kianoush, Sree Harsha Tirumani, Daniel A. Smith, Ariel Nelson, Asrar Alahmadi, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.” Emerg Radiol 27, no. 4 (August 2020): 455–60. https://doi.org/10.1007/s10140-020-01765-6.

PMID
32130542
Full Text

Miller, Natalie J., Ali Raza Khaki, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, Neeraj Agarwal, Rafael Morales-Barrera, et al. “Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.” J Urol 204, no. 1 (July 2020): 63–70. https://doi.org/10.1097/JU.0000000000000761.

PMID
31971495
Full Text

Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, John Esther, Rafael Morales-Barrera, et al. “Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.” Cancer 126, no. 6 (March 15, 2020): 1208–16. https://doi.org/10.1002/cncr.32645.

PMID
31829450
Full Text

Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, et al. “Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 329–54. https://doi.org/10.6004/jnccn.2020.0011.

PMID
32135513
Full Text

Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, et al. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” J Clin Oncol 38, no. 5 (February 10, 2020): 395–405. https://doi.org/10.1200/JCO.19.01638.

PMID
31774688
Full Text

Pages